Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

~ Amryt now has three approved commercial products and a robust clinical pipeline ~ 35.9% YoY revenue growth in Q2 to $62.8M ~ 6th consecutive quarter of positive EBITDA generation ~ Cash increased to $142.9M at June 30 from $118.6M at March 31 ~ Oleogel-S10 NDA accepted by the FDA, Priority Review granted; target PDUFA date set for November 30, 2021 ~ Raising FY 2021 revenue guidance to $210M - $215M, representing 15-18% YoY growth

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here